Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: An endocrine system-related mechanism that compromises metastatic cell resistance to vascular endothelium-induced tumor cytotoxicity

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Obrador, Elena ^a   Valles, Soraya L ^a   Benlloch, María ^b   Sirerol, J Antoni ^a   Pellicer, José A ^a   Alcácer, Javier ^c   Coronado, Javier Alcácer F ^c   Estrela, José M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^c Pathology Laboratory Quirón Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOCORTICOID RECEPTOR; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CELL INTERACTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOTHELIUM CELL; GLUTATHIONE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CELL DEATH; CELL LINE; ENDOCRINE SYSTEM; EXPERIMENTAL MELANOMA; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; NEOPLASM; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; ENDOCRINE SYSTEM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HEK293 CELLS; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, GLUCOCORTICOID;

EID: 84900405692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096466     Document Type: Article

References (67)

1. Sies H (1999) Glutathione and its role in cellular functions. Free Radic Biol Med 27: 916-921.
2. Estrela JM, Ortega A, Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181. (Pubitemid 43860449)
3. Ortega A, Mena S., and Estrela J.M. (2011) Glutathione in Cancer Cell Death. Cancers 3: 1285-1310.
4. Ortega A, Ferrer P, Carretero J, Obrador E, Asensi M, et al. (2003) Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. J Biol Chem 278: 39591-39599. (Pubitemid 37248518)
5. Obrador E, Benlloch M, Pellicer JA, Asensi M, Estrela JM (2011) Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice. J Biol Chem 286: 15716-15727.
6. Valles SL, Benlloch M, Rodriguez ML, Mena S, Pellicer JA, et al. (2013) Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6-and glutathione-dependent mechanism. J Transl Med 11: 72.
7. Franco R, Cidlowski JA (2012) Glutathione efflux and cell death. Antioxid Redox Signal 17: 1694-1713.
8. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, et al. (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11 Suppl 1: S45-55. (Pubitemid 39136798)
9. Schlossmacher G, Stevens A, White A (2011) Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211: 17-25.
10. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12: 323-334.
11. Benlloch M, Mena S, Ferrer P, Obrador E, Asensi M, et al. (2006) Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J Biol Chem 281: 69-79. (Pubitemid 43671164)
12. Bacac M, Stamenkovic I (2008) Metastatic cancer cell. Annu Rev Pathol 3: 221-247. (Pubitemid 351488281)
13. Gibellini L, Pinti M, Nasi M, De Biasi S, Roat E, et al. (2010) Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin. Cancers 2: 1288-1311.
14. Berardi MJ, Fantin VR (2011) Survival of the fittest: metabolic adaptations in cancer. Curr Opin Genet Dev 21: 59-66.
15. Bartkowiak K, Riethdorf S, Pantel K (2012) The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis. Cancer Microenviron 5: 59-72.
16. Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, et al. (2002) gamma-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 35: 74-81. (Pubitemid 34032545)
17. Carretero J, Obrador E, Anasagasti MJ, Martin JJ, Vidal-Vanaclocha F, et al. (1999) Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clin Exp Metastasis 17: 567-574. (Pubitemid 30337130)
18. Ortega AL, Carretero J, Obrador E, Gambini J, Asensi M, et al. (2003) Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. J Biol Chem 278: 13888-13897. (Pubitemid 36799929)
19. Kimura AK, Xiang JH (1986) High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants. J Natl Cancer Inst 76: 1247-1254. (Pubitemid 16093164)
20. New LS, Chan EC (2008) Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) column chemistries for the UPLC-MS-MS analysis of glutathione, glutathione disulfide, and ophthalmic acid in mouse liver and human plasma. J Chromatogr Sci 46: 209-214.
21. Asensi M, Sastre J, Pallardo FV, Garcia de la Asuncion J, Estrela JM, et al. (1994) A high-performance liquid chromatography method for measurement of oxidized glutathione in biological samples. Anal Biochem 217: 323-328. (Pubitemid 24080768)
22. Flohe L, Otting F (1984) Superoxide dismutase assays. Methods Enzymol 105: 93-104. (Pubitemid 14165376)
23. Aebi H (1984) Catalase in vitro. Methods Enzymol 105: 121-126.
24. Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105: 114-121. (Pubitemid 14165378)
25. Akerboom TP, Sies H (1981) Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 77: 373-382.
26. Shaw LM, London JW, Fetterolf D, Garfinkel D (1977) Gamma- Glutamyltransferase: kinetic properties and assay conditions when gamma-glutamyl-4-nitroanilide and its 3-carboxy derivative are used as donor substrates. Clin Chem 23: 79-85. (Pubitemid 8037911)
27. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, et al. (2010) Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898.
28. Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, et al. (2005) Acceleration of glutathione efflux and inhibition of gamma- glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 280: 6950-6959. (Pubitemid 40341251)
29. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
30. Carretero J, Obrador E, Esteve JM, Ortega A, Pellicer JA, et al. (2001) Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. J Biol Chem 276: 25775-25782.
31. Braman RS, Hendrix SA (1989) Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 61: 2715-2718. (Pubitemid 20065839)
32. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, et al. (1998) Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 27: 1249-1256. (Pubitemid 28227851)
33. Sakakibara H, Koyanagi A, Suzuki TA, Suzuki A, Ling L, et al. (2010) Effects of animal care procedures on plasma corticosterone levels in group-housed mice during the nocturnal active phase. Exp Anim 59: 637-642.
34. Meister A (1983) Selective modification of glutathione metabolism. Science 220: 472-477.
35. Meister A (1995) Glutathione biosynthesis and its inhibition. Methods Enzymol 252: 26-30.
36. Lu SC (2013) Glutathione synthesis. Biochim Biophys Acta 1830: 3143-3153.
37. Nguyen T, Sherratt PJ, Pickett CB (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233-260. (Pubitemid 37372641)
38. Wild AC, Moinova HR, Mulcahy RT (1999) Regulation of gamma- glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem 274: 33627-33636. (Pubitemid 129511675)
39. Biswas M, Chan JY (2010) Role of Nrf1 in antioxidant response element-mediated gene expression and beyond. Toxicol Appl Pharmacol 244: 16-20.
40. Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 32: 234-246.
41. Yamaura M, Mitsushita J, Furuta S, Kiniwa Y, Ashida A, et al. (2009) NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res 69: 2647-2654.
42. Rotblat B, Melino G, Knight RA (2012) NRF2 and p53: Januses in cancer? Oncotarget 3: 1272-1283.
43. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL (2013) The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol 1: 45-49.
44. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, et al. (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281: 39776-39784. (Pubitemid 46041781)
45. Kalechman Y, Strassmann G, Albeck M, Sredni B (1998) Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J Immunol 161: 3536-3542.
46. Muller PA, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218.
47. Pourova J, Kottova M, Voprsalova M, Pour M (2010) Reactive oxygen and nitrogen species in normal physiological processes. Acta Physiol (Oxf) 198: 15-35.
48. Ortega AL, Mena S, Estrela JM (2010) Oxidative and Nitrosative Stress in the Metastatic Microenvironment. Cancers 2: 274-304.
49. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y (2007) High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 212: 368-374. (Pubitemid 47025626)
50. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM (2000) Interactions between cancer cells and the endothelium in metastasis. J Pathol 190: 310-329. (Pubitemid 30141377)
51. Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90: 103-122. (Pubitemid 37548466)
52. Albertsson PA, Nannmark U, Johansson BR (1995) Melanoma cell destruction in the microvasculature of perfused hearts is reduced by pretreatment with vitamin E. Clin Exp Metastasis 13: 269-276.
53. Eskenazi AE, Pinkas J, Whitin JC, Arguello F, Cohen HJ, et al. (1993) Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. J Natl Cancer Inst 85: 711-721. (Pubitemid 23133592)
54. Antelmann H, Helmann JD (2011) Thiol-based redox switches and gene regulation. Antioxid Redox Signal 14: 1049-1063.
55. Leibowitz B, Yu J (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9: 417-422.
56. Zhang H, Forman HJ (2012) Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol 23: 722-728.
57. Cadepond F, Ulmann A, Baulieu EE (1997) RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48: 129-156. (Pubitemid 27101820)
58. Min KJ, Jang JH, Lee JT, Choi KS, Kwon TK (2012) Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J Mol Med (Berl) 90: 309-319.
59. Kratschmar DV, Calabrese D, Walsh J, Lister A, Birk J, et al. (2012) Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One 7: e36774.
60. Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298: F662-671.
61. Sephton S, Spiegel D (2003) Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17: 321-328. (Pubitemid 36999839)
62. Sahar S, Sassone-Corsi P (2009) Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9: 886-896.
63. Yu C, Yap N, Chen D, Cheng S (1997) Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53. Cancer Lett 116: 191-196. (Pubitemid 27283007)
64. Sengupta S, Wasylyk B (2004) Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann N Y Acad Sci 1024: 54-71. (Pubitemid 38879593)
65. Zhao YN, Guo X, Ma ZG, Gu L, Ge J, et al. (2011) Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells. Med Oncol 28: 1609-1617.
66. Storz P (2005) Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896.
67. Mena S, Rodriguez ML, Ortega A, Priego S, Obrador E, et al. (2012) Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1. J Transl Med 10: 8.